A Study to Assess the Safety, Tolerability, and Efficacy of ST-400 for Treatment of Transfusion-Dependent Beta-thalassemia (TDT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT03432364

Recruitment Status : Completed

First Posted : February 14, 2018

Last Update Posted : February 1, 2023

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborator:

Sanofi

Information provided by (Responsible Party):

Sangamo Therapeutics

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	November 17, 2022
Actual Study Completion Date :	November 17, 2022

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Brusson M, Miccio A. Genome editing approaches to beta-hemoglobinopathies. Prog Mol Biol Transl Sci. 2021;182:153-183. doi: 10.1016/bs.pmbts.2021.01.025. Epub 2021 Mar 1.

To Top